Clinical Trials
- HIV/AIDS, Immune System, Infectious Disease
Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population
- Ages18 years and older
- GenderBoth
- HIV/AIDS
A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)
- Ages18 years and older
- GenderBoth
- Infectious Disease, COVID-19 Inpatient, COVID-19 Outpatient
Using Smart Phones to Understand the Link Between Social and Geographical Context and HIV Risk Behavior Among MSM (GPS and Health)
- Ages18 years - 34 years
- GenderMale only
- HIV/AIDS
Mechanisms of HIV latency
- Ages18 years and older
- GenderBoth
- Infectious Disease, Men's Health, Women's Health
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults (PRIOH-1)
- Ages16 years and older
- GenderBoth
- Brain, Spinal Cord & Nervous System
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis (ExTINGUISH)
- Ages18 years and older
- GenderBoth
- Orthopaedics, Muscle & Bone, Immune System
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE (NAIVE)
- Ages18 years - 70 years
- GenderBoth
- Leukemia
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
- HIV/AIDS
Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence
- Ages18 years and older
- GenderBoth
- Hepatitis, HIV/AIDS, Immune System, Infectious Disease
Screening In Anticipation of Future Research
- Ages2 years - 17 years
- GenderBoth